Pulmonx Corporation Overview
Pro stress-test →Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The commercial-stage medical technology company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Strategic Profile
Pro stress-test →Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients. In Q2 2025, the company achieved total revenue of $23.9 million, representing a 15% year-over-year increase, driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).
Competitive Landscape
Pro stress-test →Pulmonx operates in the minimally invasive COPD treatment space with its flagship Zephyr Endobronchial Valve therapy. The market includes broader lung disease and respiratory device manufacturers, though direct competitors in minimally invasive emphysema treatment are limited. The company competes on clinical efficacy, physician training networks, and geographic market penetration.
Industry Context
Pulmonx Corporation operates in Medical Devices - Respiratory/Pulmonary Care.
Key facts
Founded: 1995 · Headquarters: Redwood City, California, United States · Employees: 291 · Revenue: $23.9M (Q2 2025) · Market cap: $150M